Cargando…

Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions

Background and Objectives: Preclinical studies have shown cannabidiol is protective in models of ischemic stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuroprotective phytocannabinoids, cannabigerol (CBG) and cannabidivarin (CBDV), on cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Stone, Nicole L., England, Timothy J., O'Sullivan, Saoirse E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380798/
https://www.ncbi.nlm.nih.gov/pubmed/33998890
http://dx.doi.org/10.1089/can.2020.0159
_version_ 1783741246430248960
author Stone, Nicole L.
England, Timothy J.
O'Sullivan, Saoirse E.
author_facet Stone, Nicole L.
England, Timothy J.
O'Sullivan, Saoirse E.
author_sort Stone, Nicole L.
collection PubMed
description Background and Objectives: Preclinical studies have shown cannabidiol is protective in models of ischemic stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuroprotective phytocannabinoids, cannabigerol (CBG) and cannabidivarin (CBDV), on cells of the blood–brain barrier (BBB), namely human brain microvascular endothelial cells (HBMECs), pericytes, and astrocytes. Experimental Approach: Cultures were subjected to oxygen-glucose deprivation (OGD) protocol to model ischemic stroke and cell culture medium was assessed for cytokines and adhesion molecules post-OGD. Astrocyte cell lysates were also analyzed for DNA damage markers. Antagonist studies were conducted where appropriate to study receptor mechanisms. Results: In astrocytes CBG and CBDV attenuated levels of interleukin-6 (IL-6) and lactate dehydrogenase (LDH), whereas CBDV (10 nM–10 μM) also decreased vascular endothelial growth factor (VEGF) secretion. CBDV (300 nM–10 μM) attenuated levels of monocyte chemoattractant protein (MCP)-1 in HBMECs. In astrocytes, CBG decreased levels of DNA damage proteins, including p53, whereas CBDV increased levels of DNA damage markers. Antagonists for CB(1), CB(2), PPAR-γ, PPAR-α, 5-HT1(A), and TRPV1 had no effect on CBG (3 μM) or CBDV (1 μM)-mediated decreases in LDH in astrocytes. GPR55 and GPR18 were partially implicated in the effects of CBDV, but no molecular target was identified for CBG. Conclusions: We show that CBG and CBDV were protective against OG mediated injury in three different cells that constitute the BBB, modulating different hallmarks of ischemic stroke pathophysiology. These data enhance our understanding of the protective effects of CBG and CBDV and warrant further investigation into these compounds in ischemic stroke. Future studies should identify other possible neuroprotective effects of CBG and CBDV and their corresponding mechanisms of action.
format Online
Article
Text
id pubmed-8380798
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-83807982021-09-01 Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions Stone, Nicole L. England, Timothy J. O'Sullivan, Saoirse E. Cannabis Cannabinoid Res Special Section: Cannabinoids and the Immune System Background and Objectives: Preclinical studies have shown cannabidiol is protective in models of ischemic stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuroprotective phytocannabinoids, cannabigerol (CBG) and cannabidivarin (CBDV), on cells of the blood–brain barrier (BBB), namely human brain microvascular endothelial cells (HBMECs), pericytes, and astrocytes. Experimental Approach: Cultures were subjected to oxygen-glucose deprivation (OGD) protocol to model ischemic stroke and cell culture medium was assessed for cytokines and adhesion molecules post-OGD. Astrocyte cell lysates were also analyzed for DNA damage markers. Antagonist studies were conducted where appropriate to study receptor mechanisms. Results: In astrocytes CBG and CBDV attenuated levels of interleukin-6 (IL-6) and lactate dehydrogenase (LDH), whereas CBDV (10 nM–10 μM) also decreased vascular endothelial growth factor (VEGF) secretion. CBDV (300 nM–10 μM) attenuated levels of monocyte chemoattractant protein (MCP)-1 in HBMECs. In astrocytes, CBG decreased levels of DNA damage proteins, including p53, whereas CBDV increased levels of DNA damage markers. Antagonists for CB(1), CB(2), PPAR-γ, PPAR-α, 5-HT1(A), and TRPV1 had no effect on CBG (3 μM) or CBDV (1 μM)-mediated decreases in LDH in astrocytes. GPR55 and GPR18 were partially implicated in the effects of CBDV, but no molecular target was identified for CBG. Conclusions: We show that CBG and CBDV were protective against OG mediated injury in three different cells that constitute the BBB, modulating different hallmarks of ischemic stroke pathophysiology. These data enhance our understanding of the protective effects of CBG and CBDV and warrant further investigation into these compounds in ischemic stroke. Future studies should identify other possible neuroprotective effects of CBG and CBDV and their corresponding mechanisms of action. Mary Ann Liebert, Inc., publishers 2021-08-05 /pmc/articles/PMC8380798/ /pubmed/33998890 http://dx.doi.org/10.1089/can.2020.0159 Text en © Nicole L. Stone et al., 2021; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Special Section: Cannabinoids and the Immune System
Stone, Nicole L.
England, Timothy J.
O'Sullivan, Saoirse E.
Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
title Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
title_full Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
title_fullStr Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
title_full_unstemmed Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
title_short Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
title_sort protective effects of cannabidivarin and cannabigerol on cells of the blood–brain barrier under ischemic conditions
topic Special Section: Cannabinoids and the Immune System
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380798/
https://www.ncbi.nlm.nih.gov/pubmed/33998890
http://dx.doi.org/10.1089/can.2020.0159
work_keys_str_mv AT stonenicolel protectiveeffectsofcannabidivarinandcannabigeroloncellsofthebloodbrainbarrierunderischemicconditions
AT englandtimothyj protectiveeffectsofcannabidivarinandcannabigeroloncellsofthebloodbrainbarrierunderischemicconditions
AT osullivansaoirsee protectiveeffectsofcannabidivarinandcannabigeroloncellsofthebloodbrainbarrierunderischemicconditions